Approval · Notice of Compliance 4122 · 1997
TAZORAC: Notice of Compliance 4122
Issued February 25, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4122
- Date
- February 25, 1997
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Anti-psoriatic, anti-acne
Products in this notice
Medicinal ingredients
- TAZAROTENE 0.05 PER
- TAZAROTENE 0.1 PER